UDC 616.65-006.6-089-07:616.633-07

At present, the identification of high-risk groups of localized prostate cancer (PCa) is highly relevant. Our previous research demonstrated that prostate cancer antigen 3 (PCA3) scores depend on the tumor zone of origin (TZO) and the tumor growth dominant pattern (TGDP).
The aim: to assess the prognostic value of PCA3 score for identifying postoperative 4–5 grade group according to the International Society of Urological Pathology 2014 (ISUP) classification in patients with localized peripheral zone prostate cancer with posterior TGDP (pPZ-PCa).
Materials and methods. PCA3 scores and correlations were assessed and compared in different PCa patient groups and subgroups based on TZO, TGDP, and ISUP grade. Receiver operating characteristic curve (ROC) analysis was used to evaluate the diagnostic significance of the model and determine the optimal PCA3 score cutoff for identifying ISUP 4–5.
Results. The PCA3 scores showed a significant (p<0.01) positive correlation (r=0.71) with ISUP grade in pPZPCa. PCA3 scores differed significantly (p<0.01) between ISUP 1–3 and 4–5 pPZ-PCa subgroups. ROC analysis demonstrated excellent performance with an AUC of 0.98 (95% CI: 0.95–0.99) for identifying ISUP 4–5 pPZ-PCa.
Conclusions. PCA3 scores demonstrated prognostic value for identifying postoperative ISUP 4–5 in pPZ-PCa.

Urinary bladder cancer (UBC) is a prevalent malignancy worldwide, exhibiting high recurrence rates and significant morbidity and mortality. Traditional diagnostic and prognostic methods often fall short in providing the precision required for effective patient stratification and personalized treatment. Genomic and transcriptomic studies have revolutionized our understanding of UBC by unveiling molecular alterations that drive tumor initiation, progression, and therapeutic response. This systematic review explores the role and application of genomic and transcriptomic analyses in the diagnostics and survival prediction of non-invasive and invasive UBC. We conducted a comprehensive literature search in MEDLINE, Web of Science, and Scopus up to October 2023, adhering to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Our search yielded 1,256 records (412 in MEDLINE, 378 in Web of Science, and 466 in Scopus), and 356 duplicates were removed. Our findings highlight key mechanisms of action, including mutations in FGFR3, TP53, and RB1 genes, and alterations in pathways such as PI3K/AKT/mTOR and MAPK/ERK, which are pivotal in UBC pathogenesis. Recent research advances, including liquid biopsies and single-cell sequencing, offer promising non-invasive diagnostic tools and deeper insights into tumor heterogeneity. This review underscores the critical importance of integrating genomic and transcriptomic data into clinical practice to improve diagnostics, prognostic assessments, and personalized treatment strategies for UBC patients. Future research should focus on integrating multi-omics data and validating molecular biomarkers in large clinical trials to further enhance patient outcomes.